MA52076A - Anticorps anti-cd137 pour une combinaison avec des anticorps anti-pd-1 - Google Patents

Anticorps anti-cd137 pour une combinaison avec des anticorps anti-pd-1

Info

Publication number
MA52076A
MA52076A MA052076A MA52076A MA52076A MA 52076 A MA52076 A MA 52076A MA 052076 A MA052076 A MA 052076A MA 52076 A MA52076 A MA 52076A MA 52076 A MA52076 A MA 52076A
Authority
MA
Morocco
Prior art keywords
antibodies
combination
Prior art date
Application number
MA052076A
Other languages
English (en)
Inventor
Michael Dewain Kalos
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA52076A publication Critical patent/MA52076A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)
MA052076A 2018-03-23 2019-03-15 Anticorps anti-cd137 pour une combinaison avec des anticorps anti-pd-1 MA52076A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862647046P 2018-03-23 2018-03-23

Publications (1)

Publication Number Publication Date
MA52076A true MA52076A (fr) 2021-01-27

Family

ID=65952175

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052076A MA52076A (fr) 2018-03-23 2019-03-15 Anticorps anti-cd137 pour une combinaison avec des anticorps anti-pd-1

Country Status (11)

Country Link
US (2) US20210054089A1 (fr)
EP (1) EP3768712A1 (fr)
JP (1) JP7059389B2 (fr)
KR (3) KR20250038810A (fr)
CN (1) CN112041346B (fr)
CA (1) CA3094998C (fr)
EA (1) EA202092262A1 (fr)
IL (1) IL277511A (fr)
MA (1) MA52076A (fr)
MX (1) MX2020009864A (fr)
WO (1) WO2019182879A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112020517B (zh) 2018-03-23 2024-10-29 伊莱利利公司 用于与抗pd-l1抗体组合的抗cd137抗体
JP7432716B2 (ja) * 2019-11-13 2024-02-16 合肥瀚科邁博生物技術有限公司 ヒト４－１ｂｂに結合可能な分子及びその応用
CN117321079A (zh) * 2021-01-11 2023-12-29 优特力克斯有限公司 包含抗4-1bb抗体及pd-1蛋白或其片段的双特异性表位结合蛋白及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7288638B2 (en) 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
CN103221428B (zh) 2010-09-09 2016-02-10 辉瑞公司 4-1bb结合分子
ES2716685T3 (es) 2014-01-24 2019-06-14 Dana Farber Cancer Inst Inc Moléculas de anticuerpo para PD-1 y usos de las mismas
EP3686219A1 (fr) * 2014-02-04 2020-07-29 Pfizer Inc Combinaison d'un antagoniste de pd -1 et d'un agoniste de 4-1bb pour le traitement du cancer
JP6868394B2 (ja) * 2014-05-16 2021-05-12 ファイザー・インク 二重特異性抗体
US20170247455A1 (en) * 2014-08-22 2017-08-31 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
CN112587672A (zh) * 2014-09-01 2021-04-02 博笛生物科技有限公司 用于治疗肿瘤的抗-pd-l1结合物
WO2017024465A1 (fr) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Anticorps anti-pd-1
PE20200839A1 (es) * 2017-08-01 2020-08-13 Lilly Co Eli Anticuerpos anti-cd137
CN112020517B (zh) * 2018-03-23 2024-10-29 伊莱利利公司 用于与抗pd-l1抗体组合的抗cd137抗体

Also Published As

Publication number Publication date
US20210054089A1 (en) 2021-02-25
AU2019237977A1 (en) 2022-01-20
IL277511A (en) 2020-11-30
KR20250038810A (ko) 2025-03-19
EP3768712A1 (fr) 2021-01-27
CN112041346A (zh) 2020-12-04
US20250333525A1 (en) 2025-10-30
CA3094998A1 (fr) 2019-09-26
EA202092262A1 (ru) 2021-01-14
KR20240017090A (ko) 2024-02-06
NZ768428A (en) 2024-08-30
CA3094998C (fr) 2023-05-09
KR20200134288A (ko) 2020-12-01
JP2021516251A (ja) 2021-07-01
JP7059389B2 (ja) 2022-04-25
CN112041346B (zh) 2024-10-22
MX2020009864A (es) 2021-01-08
WO2019182879A1 (fr) 2019-09-26

Similar Documents

Publication Publication Date Title
MA48604A (fr) Anticorps anti-tim-3 pour une combinaison avec des anticorps anti-pd-1
MA46952A (fr) Anticorps anti-pd-l1 radiomarqués pour imagerie immuno-pet
MA52742A (fr) Anticorps bispécifiques dll3-cd3
MA52884A (fr) Anticorps anti-il-11
MA53434A (fr) Anticorps anti-tigit
EP3903817A4 (fr) Nouvel anticorps anti-ccr8
MA52366A (fr) Anticorps anti-tl1a optimisés
MA53905A (fr) Anticorps stabilisant trem2
EP3765522A4 (fr) Anticorps anti-claudine 18.2
EP3883970A4 (fr) Anticorps anti-b7-h3
EP3441086A4 (fr) Anticorps monoclonal anti-pd-1
MA49749A (fr) Anticorps anti-cd137
EP3503920A4 (fr) Anticorps anti-ctla4
MA47456A (fr) Anticorps anti-lag3 radiomarqués pour imagerie immuno-pet
EP3630078A4 (fr) Agents pour chimio-embolisation
EP3648801A4 (fr) Compositions de dota-haptène pour une radioimmunothérapie préciblée par un anticorps bispécifique antigène anti-dota/anti-tumoral
EP3885367A4 (fr) Anticorps bispécifique anti-her2/pd1
EP3512885A4 (fr) Anticorps anti-pd-1
EP3496753A4 (fr) Formulation d'anticorps anti-pd-1
EP3383915A4 (fr) Anticorps anti-pd-1
EP3247718A4 (fr) Modulation de variants de charge dans une composition d'anticorps monoclonaux
EP3746120A4 (fr) Anticorps anti-pd-1
MA52545A (fr) Anticorps pour radionucléides chélatés
EP3752536A4 (fr) Anticorps anti-her2
EP3692072A4 (fr) Anticorps anti-hla-dq2.5